Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

235.67 +2.66 (+1.14%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

3 Unpopular Stocks We Find Risky

June 08, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Topics Credit Cards

Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge ↗

June 05, 2026

Via Chartmill

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.

Via The Motley Fool

Topics Regulatory Compliance

3 Healthcare Stocks We Think Twice About

May 29, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...

Via StockStory

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat ↗

May 05, 2026

Via Chartmill

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Beats Q4 Estimates but 2026 Guidance Tempers Gains ↗

February 24, 2026

Via Chartmill

3 Mid-Cap Stocks We’re Skeptical Of

May 25, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Is Marriott Stock a Buy After GMT Capital Initiated a Position Worth Over $66 Million? ↗

May 20, 2026

This hospitality firm runs 120+ upscale vacation properties worldwide, leveraging exclusive brands and recurring fee-based revenue.

Via The Motley Fool

Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 12, 2026

Jazz Pharmaceuticals delivered a first quarter that was met with a positive response from the market, driven largely by strong commercial execution across it...

Via StockStory

Topics Earnings

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

May 06, 2026

What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong first-qu...

Via StockStory

JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals

May 06, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 19.1% year on year ...

Via StockStory

Jazz (JAZZ) Q1 2026 Earnings Call Transcript ↗

May 05, 2026

Jazz (JAZZ) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales

May 05, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced better-than-expected revenue in Q1 CY2026, with sales up 19.1% year on year to $1.07 billion. ...

Via StockStory

Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For

May 03, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know. Jazz Pharmaceut...

Via StockStory

Topics Artificial Intelligence

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

April 26, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Overrated Stocks with Warning Signs

April 23, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Via StockStory

3 Reasons to Sell JAZZ and 1 Stock to Buy Instead

April 21, 2026

What a time it’s been for Jazz Pharmaceuticals. In the past six months alone, the company’s stock price has increased by a massive 46%, reaching $200.71 per ...

Via StockStory

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

1 Value Stock to Research Further and 2 We Ignore

March 18, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

3 Healthcare Stocks Walking a Fine Line

March 13, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...

Via StockStory

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

February 25, 2026

Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 13.5% in the afternoon session after the company reported better-than-expected fourth-quarter 2025 revenue and earnings.

Via StockStory

Topics Artificial Intelligence Supply Chain

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

February 24, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.1% year on year to $1.20 billion. On the other hand, the...

Via StockStory

Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

February 22, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence Government World Trade

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

February 15, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid

February 10, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 Cash-Producing Stocks We Think Twice About

February 05, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24% ↗

January 29, 2026

Vipshop Holdings is a major Chinese e-commerce retailer specializing in branded discount sales for value-focused consumers.

Via The Motley Fool

Topics Economy

This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding ↗

January 29, 2026

Via The Motley Fool

Topics Credit Cards ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.